|
Pharmacologic Relapse Prevention for Alcoholic Smokers Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on Pharmacologic Relapse Prevention for Alcoholic Smokers conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Pharmacologic Relapse Prevention for Alcoholic Smokers Clinical research trials and Pharmacologic Relapse Prevention for Alcoholic Smokers medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including Pharmacologic Relapse Prevention for Alcoholic Smokers. Pharmacologic Relapse Prevention for Alcoholic Smokers Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Pharmacologic Relapse Prevention for Alcoholic Smokers clinical trial. Participants oftentimes recieve the finest healthcare available for their Pharmacologic Relapse Prevention for Alcoholic Smokers condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Pharmacologic Relapse Prevention for Alcoholic Smokers  Pharmacologic Relapse Prevention for Alcoholic Smokers
Pharmacologic Relapse Prevention for Alcoholic Smokers
For Condition: Alcoholism,Smoking
Status: Completed
Sponsor(s): National Institute on Alcohol Abuse and Alcoholism (NIAAA) ,
Synopsis: This study will compare the long-term use of bupropion (Wellbutrin) and placebo for reducing the rate of smoking relapse in recovering alcoholics who achieved initial abstinence from smoking with nicotine patch therapy. The study will also determine the cessation rate in the 8th week of treatment among recovering alcoholics using a nicotine patch. The patch dose is projected to serve as a 100-percent replacement.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - History of alcohol dependence and at least one year of abstinence from alcohol intake. - Has a history of smoking 20 or more cigarettes per day for the prior year. - Can read and write English. - Stated ability to fully participate in the study and keep all scheduled appointments. - Has provided written informed consent. - General good health. Exclusion Criteria: - Recent history (within three months) of a clinically significant myocardial infarction, unstable angina pectoris, serious cardiac arrhythmia or any other medical condition which the physician investigator deems incompatible with study participation. - Current major depression. A past history of major depression will not be an exclusionary criteria. - Current or previous use of bupropion (Wellbutrin). - Active non- nicotine drug dependence. - Past or current history of bipolar disorder, pain disorder or psychosis, schizophrenia, or other major psychiatric disorders. - Current medically indicated use of psychiatric drugs. - Females who are pregnant, lactating, or likely to become pregnant during the first year which includes the nicotine patch and bupropion (Wellbutrin) phase. - History of severe skin allergies or evidence of severe chronic skin disorders. - Current use of nicotine containing medication or tobacco products other than cigarettes. - Current use (within 30 days of initiation of patch therapy) of the following medications for smoking cessation: clonidine, buspirone, or doxepin. - A predisposition to seizures. - A history of or current diagnosis of anorexia nervosa or bulimia. - Medical disorder that would interfere with the absorption, metabolism, or excretion of bupropion (Wellbutrin).
Total Enrollment: 292
Location and Contact Information:
Mayo Clinic Rochester
Rochester, Minnesota, 55905
United States
Additional Information:
Study ID Numbers: NIAAAHUR11219;
Study Start Date:
Record last reviewed: August 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000457
Other Smoking Studies:
1. Tobacco Dependence in Alcoholism Treatment (nicotine patch/naltrexone)
2. Facilitating Implementation of the U.S. Public Health Service Smoking Cessation Guideline
3. A Randomized Trial to Implement the AHCPR Smoking Cessation Guideline
4. Anti-Smoking Program for Parents: Effects on Child Smoking
5. Theory-based Interventions for Smoking and Obesity (Challenge) Trial
Related Studies:
Other Smoking Clinical Trials
Other Minnesota Clinical Trials
Other Rochester Clinical Trials
Pharmacologic Relapse Prevention for Alcoholic Smokers
|
|
|
|
|
|
|
|
